Treatment News : HPV Vaccine May Protect With Two Doses Instead of Three

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 17, 2013

HPV Vaccine May Protect With Two Doses Instead of Three

A trial to determine the effectiveness of the human papillomavirus (HPV) vaccine Gardasil given in two doses instead of the current standard of three suggests that reducing the dosage may be feasible, MedPage Today reports. However, much more research is needed, and there are detractors arguing against such a shift. In a randomized Phase III trial, investigators studied 830 Canadian girls and young women given differing doses of the vaccine between August 2007 and February 2011. In the end, 675 participants provided follow-up samples. The researchers reported their findings in The Journal of the American Medical Association.

Girls between the ages of 9 and 13 were randomized evenly to receive either three doses of Gardasil (261 girls) at 0, 2 and 6 months or two doses at 0 and 6 months (259 girls). In addition, 310 young women ages 16 to 26 received the three-dose schedule. Investigators measured antibody levels at 0, 7, 18, 24 and 36 months.

Among the girls who took two doses of the vaccine, their responses to strains 16 and 18 of HPV one month after their last vaccine dose proved “noninferior,” or as good as, the responses of the young women receiving three doses. However, noninferiority to some HPV genotypes dissipated at the 24- and 36-month assessments when comparing the girls who took two doses with the girls (as opposed to the young women) who took three doses. Consequently, the investigators concluded that more study is needed before recommending a dose reduction as a matter of policy.

To read the MedPage Today story, click here.

To read the JAMA abstract, click here.

To read an accompanying JAMA editorial questioning two-dose vaccines, click here.

Search: HPV, human papillomavirus, vaccine, Gardasil, MedPage Today, Journal of the American Medical Association.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.